PT - JOURNAL ARTICLE AU - Sun Tian AU - Fulong Wang AU - Shixun Lu AU - Rujia Wu AU - Gong Chen TI - An iterative supervised learning method identifying two subgroups of FOLFOX resistance patterns and predicting FOLFOX response in colorectal cancer patients AID - 10.1101/2020.06.10.20127167 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.10.20127167 4099 - http://medrxiv.org/content/early/2020/06/11/2020.06.10.20127167.short 4100 - http://medrxiv.org/content/early/2020/06/11/2020.06.10.20127167.full AB - Background FOLFOX is a combination of drugs that is widely used to treat colorectal cancer. The response rate of FOLFOX in colorectal cancer(CRC) is 30-50%. We develop a method that analyzes mechanisms of FOLFOX resistance and predicts whether a patient will benefit from FOLFOX.Methods Gene expression data of 83 stage IV CRC tumor samples (FOLFOX responder n=42, non-responder n=41) were used to develop a supervised learning method IML and analyze subgroups of FOLFOX resistance mechanism. Datasets of 32 FOLFOX treated stage IV CRC patients and 55 FOLFOX treated stage III CRC patients were used as independent validations.Results An iterative supervised learning (IML) method identified two distinct subgroups of CRC patients who resist FOLFOX. Each subgroup relies on different types of DNA damage repair proteins and they are mutually exclusive. Protein-protein networks showed the main mechanism might be the synergistic effect of resisting apoptosis and an altered cell cycle. IML method was validated in two independent validation sets, one FOLFOX treated stage IV CRC patients(HR=2.6, p-value=0.02, 3-years survival rate of the predicted responder group 61.9%, predicted nonresponder group 18.8%) and one FOLFOX treated stage III CRC patients (estimated HR=2.36, p-value=0.02). A subgroup of mesenchymal subtype patients shows the pattern as FOLFOX responders.Conclusions IML method reflects the underlying biology of FOLFOX resistance and predicts FOLFOX response.Competing Interest StatementST and RW have stocks and/or stock options in Carbon Logic Biotech (HK) Ltd. ST and GC are named inventors of a patent application relevant to the presented work. All remaining authors have declared no conflicts of interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No human or animal ethics approval was required for this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData generated for the current study are available from the corresponding author on reasonable request.